{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.9","upperLimit":"60.1","value":"50.0"},{"groupId":"OG001","lowerLimit":"41.3","upperLimit":"70.0","value":"56.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"description":"Confirmed objective response rate (ORR), defined as the proportion of participants with complete response (CR) or partial response (PR), was assessed by blinded independent central review (BICR) based on Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants randomized to receive trastuzumab deruxtecan 5.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).","id":"OG000","title":"Trastuzumab Deruxtecan 5.4 mg/kg"},{"description":"Participants randomized to receive trastuzumab deruxtecan 6.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).","id":"OG001","title":"Trastuzumab Deruxtecan 6.4 mg/kg"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set includes all subjects for whom study treatment was assigned by randomization","reportingStatus":"POSTED","timeFrame":"9 months after the last participant is randomized to data cut off, up to approximately 21 months","title":"Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer","type":"PRIMARY","unitOfMeasure":"percentage of participants"}